You are here: Industry Insights > COVID-19

News List

Immune Regulation teams with DynPort on COVID-19 drug pharmatimes
July 07, 2020
US and UK-based clinical stage biotech Immune Regulation has signed a deal with DynPort Vaccine Company to jointly evaluate the potential of the former's ILR201104 to treat COVID-19 related Acute Respiratory Distress Syndrome (ARDS) in US clinical trials.
Using Epo against COVID-19 worldpharmanews
July 07, 2020
Erythropoietin (Epo) is actually a medication for anaemia. According to researchers at the Max Planck Institute of Experimental Medicine in G?ttingen, the doping agent Epo could also be effective against COVID-19.
FDA, EC Partner on COVID-19 Response americanpharmaceuticalreview
July 07, 2020
The European Union (EU) is one of the U.S. Food and Drug Administration’s most important collaborators in tackling public heath challenges.
Cytocom Announces Successful FDA Meeting for CYTO-201 Trial in COVID-19 Patients americanpharmaceuticalreview
July 07, 2020
Cytocom announced the successful completion of a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) in relation to the Company's planned Phase 2 clinical trial of CYTO-201 for the treatment of SARS-CoV-2, the virus responsible for ...
New next-generation research platform launched by Genomics England europeanpharmaceuticalreview
July 07, 2020
The genomic research platform will initially be used to help fast-track COVID-19 drug research and development, before being leveraged against other diseases, such as cancer.
Gilead gets EC conditional approval for remdesivir to treat Covid-19 pharmaceutical-technology
July 07, 2020
The European Commission (EC) has provided conditional marketing authorisation for Gilead Sciences to use Veklury (remdesivir) for the treatment of Covid-19.
Medivir and SciLifeLab partner to identify Covid-19 drug candidates pharmaceutical-technology
July 07, 2020
Swedish drug development company Medivir has partnered with SciLifeLab, a life science research firm, to identify compounds with the potential to inhibit SARS-CoV-2, the novel coronavirus that causes Covid-19.
Hundreds of scientists say coronavirus is airborne, ask WHO to revise recommendations: NYT expresspharma
July 07, 2020
The WHO has said the coronavirus disease spreads primarily from person to person through small droplets from the nose or mouth.
Experts ask govt to ensure access to remdesivir, raise concerns about supply shortage expresspharma
July 07, 2020
Many also allude to an emerging black market for remdesivir in the country through which the drug is being sold at exorbitant prices per vial.
Zydus gets nod from COFEPRIS, Mexico to study Desidustat for COVID-19 management expresspharma
July 07, 2020
As a part of the study, 100 mg tablets of Desidustat will be administered for a period of 14 days along with recommended standard care during the trial.